For Investors & BD Teams
Buy-Side Diligence
Independent preclinical assessment from someone who has been on the buy-side, evaluating companies for transactions up to $11B. We know what questions matter and where the gaps hide.
Two Formats
Choose the depth that matches your deal timeline.
Rapid Screen
48-hour turnaround
- Go/watch/pass recommendation
- Scientific rationale assessment
- Key risks identified
- Competitive positioning snapshot
- 2-3 page memo delivered in 48 hours
For active deal flow screening when you need a fast, informed read.
Diligence Memo
2-4 weeks
- Comprehensive preclinical assessment
- Competitive positioning and landscape
- Risk register with mitigations
- Key questions for management
- Development timeline and cost analysis
- Delivered in 2-4 weeks
For deeper evaluation before term sheets or partnership decisions.
What Sets This Apart
Most diligence consultants have only worked on one side of the table.
Our founder has sat on both sides: designed IND-enabling preclinical programs as an operator AND evaluated companies as acquisition and partnership targets for transactions up to $11B. We know what questions the operating team cannot answer, and we know what gaps the acquirer or investor will find. That dual perspective is what makes our diligence assessments different.
Who This Is For
VCs screening preclinical-stage deal flow
Pharma BD teams evaluating partnership or acquisition targets
Family offices and crossover funds assessing biotech assets
Need an Independent Assessment?
Book a call to discuss the target company. Confidential, no obligation.
Book a Strategy Call30-minute call · No obligation · Confidential
info@bridgelinetranslational.com · bridgelinetranslational.com